What Next for Immunomedics Inc (NASDAQ:IMMU) Stock After Increase in Shorted Shares?

Immunomedics, Inc. (NASDAQ:IMMU) Logo

Investors sentiment increased to 1.69 in 2019 Q2. Its up 0.40, from 1.29 in 2019Q1. It is positive, as 21 investors sold Immunomedics, Inc. shares while 38 reduced holdings. 30 funds opened positions while 70 raised stakes. 155.91 million shares or 2.56% less from 160.01 million shares in 2019Q1 were reported.
Exane Derivatives stated it has 138 shares. Jane Street Grp Ltd Company owns 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 24,205 shares. Moreover, State Bank Of New York Mellon Corp has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Oppenheimer Asset Inc reported 26,663 shares. Sg Americas Limited Liability, a New York-based fund reported 7,336 shares. Goldman Sachs Group Inc Incorporated invested in 0% or 1.08M shares. Macquarie Group Incorporated Ltd invested 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). First Light Asset Mngmt Lc holds 1.22 million shares. Nicholas Investment Prns L P owns 314,912 shares or 0.4% of their US portfolio. Aperio Gp Ltd Liability invested in 11,430 shares or 0% of the stock. Financial Bank Of Montreal Can accumulated 15,686 shares or 0% of the stock. Smith Asset Gp Limited Partnership owns 3,870 shares. Menora Mivtachim has invested 0.19% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). 12,507 were reported by Mariner Limited Liability Company. Geode Cap Mgmt Limited Com holds 2.30 million shares.

Since May 13, 2019, it had 4 insider buys, and 0 insider sales for $43.69 million activity. BALL BRYAN bought $66,750 worth of Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, June 20.

The stock of Immunomedics Inc (NASDAQ:IMMU) registered an increase of 10.26% in short interest. IMMU’s total short interest was 36.36M shares in September as published by FINRA. Its up 10.26% from 32.97M shares, reported previously. With 2.77 million shares average volume, it will take short sellers 13 days to cover their IMMU’s short positions.

The stock increased 6.39% or $1.01 during the last trading session, reaching $16.73. About 1.85M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has declined 34.91% since September 13, 2018 and is downtrending. It has underperformed by 34.91% the S&P500.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $3.21 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Nasdaq.com which released: “Health Care Sector Update for 04/10/2019: PTE,IMMU,GH,OTLK – Nasdaq” on April 10, 2019, also Globenewswire.com with their article: “Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update – GlobeNewswire” published on August 07, 2019, Nasdaq.com published: “Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress – Nasdaq” on September 12, 2019. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Nasdaq.com and their article: “Notable Monday Option Activity: CSOD, IMMU, CVS – Nasdaq” published on June 03, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy Tuesday Option Activity: BSX, BEAT, IMMU – Nasdaq” with publication date: September 10, 2019.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.